

**Bibliography Dr. Jochen Imig**  
**ORCID ID: 0000-0003-0385-1081**

**Key publications**

- "Targeting an RNA-binding Protein Network in Acute Myeloid Leukemia", Wang, E., Lu, S.X., Pastore, A., Chen, X. **Imig, J.**, Chun-Wei, S. Lee, Ghebrechristos, Y.E., Yoshimi, A., Bitner, L., Kloetgen, A., Lin, K.T., Uehara, T., Owa, T., Tibes, R., Krainer, A.R., Abdel-Wahab, O.\*, and Aifantis. I.\*, **Cancer Cell**, 2019, Mar 18;35(3):369-384.e7, \*equally,

- "MiR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR- 106a interaction", **Imig, J.\***, Brunschweiger, A.\*, Brümmer, A., Guennewig, B., Mittal, N., Kishore, S., Gerber, A.P., Zavolan, M., and Hall, J., **Nat Chem Biol**, 2015 Feb;11(2):107-14; \*equally

- "Stereochemical bias introduced during RNA synthesis modulates the pharmacological properties of phosphorothioate siRNAs", Jahns, H., Roos, M., **Imig, J.**, Baumann, F., Wang, Y., Gilmour R., and Hall, J., **Nat Comm**, 2015 Mar 6;6:6317

- "Epigenetic silencing of CDR1as drives IGF2BP3-mediated melanoma invasion and metastasis", Hanniford, D., Ulloa-Morales, A., Karz, A., Berzoti-Coelho, M.G., Moubarak, S.R., Sánchez-Sendra, B., Kloetgen, K., Davalos, V., **Imig, J.**, Wu, P., Vasudevaraja, V., Argibay, D., Lilja, K., Tabaglio, T., Monteagudo, C., Guccione, E., Tsirigous, A., Osman, I., Aifantis. I., and Hernando, E., **Cancer Cell**, 2020, Volume 37, Issue 1, 55-70.e15

**2017-22**

1) "Evaluation of RNase L Activation and Anticancer Activity of 2-Amino-thiophenone-3-carboxylates", Jimin, H., Borgelt, L., Xiaqiu, Q., Haacke, N., Kanis, L., Gasper, R., Stavroula, P., Lampe, P., Sievers, S., **Imig, J.**, Peng, W., 2021, **Biorg Med Chem**, 2022, Mar 15;58:116653. Epub 2022 Feb 5.

2) "Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma", Carcamo, S., Grossi, E., Nguyen, C.B., Filipescu, D., Alpsy, A., Narang, S., **Imig, J.**; Tiphaine C., Martin T.C, Parsons, R., Aifantis, I., Tsirigous, A.,

Dykhuizen, E.C, Aguirre-Ghiso, J.A., Hasson, D., Bernstein, E., **Cell Reports**, 2022, 2022, Cell Reports 39, 110637

- 3) "MINA-1 and WAGO-4 are part of regulatory network coordinating germ cell death and RNAi", Sendoel S., Subasic, S., Ducoli, L., Keller M., Michel M., Kohler, I., Singh, K. D., Zheng, X., Brümmer A., **Imig, J.**, Kishore, S., Kanitz A., Andres, A., Mittal, N., Wu, Y., Matia-González, A. M., Gerber. A., Zavolan Z., Aebersold. R., Hall, J., Allain. F.H.T., and Hengartner, M.O., **Cell Death Diff**, 2019, Oct;26(10):2157-2178.
- 4) "Anti-HIV Replicative Effect of Small Molecule Enoxacin by Modulation of Pro-viral miR-132", Schlösser, V.\* , Lightfoot, H.J.\* , Vongrad, V., Leemann, C., Brunschweiler, A., Hall, J. Metzner, K. J.# and **Imig, J.#**, 2022 under preparation, #,\* equally

## 2016

- 5) "Post-transcriptional control of executioner caspases by RNA-binding proteins",Subasic, D., Stoeger, T., Eisenring, S., Matia-Gonzalez, A. M., **Imig, J.**, Zheng, X., Xiong, L., Gisler, P., Eberhard, R., Holtackers, R., Gerber, A.P., Pelkmans, L., Hengartner, M.O., **Genes Dev**, 2016 Oct 1;30(19):2213-2225.

## 2015

- 6) "Cooperative target mRNA destabilization and translation inhibition by miR-58 microRNA family in *C. elegans*", Subasic, D., Brümmer, A., Wu, Y., Pinto, S. M., **Imig, J.**, Keller, M., Jovanovic, M., Lightfoot, H. L., Nasso, S., Goetze, S., Brunner, E., Hall, J., Aebersold, R., Zavolan, M. and Hengartner, M. O., **Genome Res.**, 2015, Jul 31. pii: gr.183160.114
- 7) „HIV-1 RNAs are not part of the Argonaute 2 associated RNA interference pathway in macrophages", **Imig, J.**,\* Vongrad, V.,\* Mohammadi, P.,\* Kishore, S., Jaskiewicz, L., Hall, J., Günthard, H. F., Beerenwinkel, N., and Metzner, K. J.\*; **Plos One**, 2015, Jul 30;10(7):e0132127, \*equally

## 2013

- 8) "Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas", Zimmermann, A.K., **Imig, J.**, Klar, A., Renner, C., Korol, D., Fink, D., Stadlmann, S., Singer, G., Knuth, A., Moch, H., Caduff, R., 2013, **Virchows Arch.**, May;462(5):565-74

- 9) "Systematic screens of proteins binding to synthetic microRNA precursors", Towbin, H., Wenter, P., Guennewig, B., **Imig, J.**, Zagalak, J.A., Gerber, A.P. and Hall, J., 2013, **Nucleic Acids Res.**, Feb 1;41(3):e47

## 2012

- 10) "The Expression Levels of MicroRNA-361-5p and Its Target VEGFA Are Inversely Correlated in Human Cutaneous Squamous Cell Carcinoma", Kanitz, A., **Imig, J.**, Dziunycz, P., Primorac, A., Galgano, A., Hofbauer, G.F.L., Gerber, A.P. and Detmar, M., 2012, **Plos one**, 7(11):e49568
- 11) "MicroRNA-142 is Mutated in About 20% of Diffuse Large B-Cell Lymphoma (DLBCL)", Kwanhian, W., Lenze, D., Alle, J., Motsch, N., Barth, S., Döll, C., **Imig, J.**, Hummel, M., Tinguely, M., Trivedi, P., Lulitanond, V., Meister, G., Renner C., Grässer, F.A., 2012, **Cancer Medicine**, Oct 2012, Vol 1, Issue 2, p i-ii, 105–288
- 12) "microRNA profiling of Epstein-Barr virus-associated NK/T cell lymphomas by deep sequencing", Motsch, N., Alles, J., **Imig, J.**, Zhu, JY., Barth, S., Reineke, T., Tinguely, M., Cogliatti, S., Dueck, A., Meister, G., Renner, C. and Grässer, F.A., Plos One, 2012, **PLoS One**, 2012;7(8):e42193. Epub 2012 Aug 3.
- 13) "RNA regulons and the RNA-protein interaction network", **Imig, J.**,\* Kanitz, A.\* and Gerber, A.P., review, **BioMol Concepts**, 2012, Vol 3, issue 5 (Oct 2012), pp. 395 - 486, \*equally

## 2011

- 14) "Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1", Craig, V.J., Cogliatti, S.B., **Imig, J.**, Renner, C., Neuenschwander, S., Rehrauer, H., Schlapbach, R., Dirnhofer, S., Tzankov, A., Müller A., **Blood**, 2011, Jun 9;117 (23):6227-36

## 2010

- 15) "microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma", Imig, J.\*, Motsch N.\*, Zhu JY, Barth, S., Okoniewski, M., Reineke T, Tinguely, M., Faggioni, A., Trivedi. P., Meister, G., Renner C., Grässer, F.A., **Nucleic Acids Res.** 2011 Mar, 39(5):1880-93, \*equally
- 16) "Yeast-based identification of prostate tumor antigens provides an effective vaccine platform", Jung, V., Fischer, E., **Imig, J.**, Kleber, S., Nuber, N.,

Reinshagen, F., Kamradt, J., Grobholz R., Knuth, A., Renner, C., Wadle, A., **Anticancer Res.**, 2010, 30(3): 895-902

### **2005-2006**

- 17) "Allosteric activation of the protein kinase PDK1 with low molecular weight compounds", Engel, M., Hindie, V., Lopez-Garcia, L.A., Stroba, A., Schaeffer, F., Adrian, I., **Imig, J.**, Idrissova, L., Nastainczyk, W., Zeuzem, S., Alzari, P.M., Hartmann, R.W., Piiper, A., Biondi, R.M., **EMBO J.** 2006 Nov 29;25(23):5469-80
- 18) "Serological immune response to cancer testis antigens in patients with pancreatic carcinomas", Wadle, Kubuschok, **Imig, J.** et al.," **Int J Cancer.** 2006 Jul 1;119(1):117-25
- 19) "Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells", Kiermayer, S., Biondi, R.M., **Imig, J.**, Plotz, G., Haupenthal, J., Zeuzem, S. and Piiper, A., 2005, **Mol Biol Cell.** Dec;16(12):5639-48
- 20) "Characterization of Hap/BAG-1 variants as RP1 binding proteins with antiapoptotic activity", Wadle, A., Mischo, A., Henrich, P.P., Stenner-Liewen, F., Scherer, C., **Imig, J.**, Petersen, G., Pfreundschuh, M., Renner, C., **Int J Cancer.** 2005 Jun 28
- 21) „Serological identification of breast cancer related antigens from a *Saccharomyces cerevisiae* surface display library“, Wadle, A., Mischo, A., **Imig, J.**, Wüllner, B., Hensel, D., Wätzig, K., Neumann, F., Kubuschok, B., Schmidt, W., Old, L.J., Pfreundschuh, M., and Renner, C., **Int. J. Cancer** 2005 Oct 20;117 (1):104-13.

### **Current Projects/Publications as (Co-)Senior authors (unpublished)**

- 1) "Topological Associated Domain Disruption Analysis in Melanoma and Melanoma Drug Resistance", Narang, S., Kloetgen, A. et al., Bernstein, E.\*, Tsirigos, A\*. Aifantis.\*, I. **Imig, J.\***
- 2) "lncRNA expression profiling and functional CRISPR-Cas9 screening in malignant melanoma", Petroulia, S., Hockemeyer, K. Kloetgen, A., et al., Tsirigos, A., Iman, O., Hernando, E., Aifantis.\*, I. **Imig, J.\***
- 3) "lncRNA expression profiling and functional CRISPR-Cas9 screening in malignant melanoma BRAFi resistance ", Petroulia, S., Hockemeyer, K. Kloetgen, A., et al., Tsirigos, A., Iman, O., Hernando, E., Aifantis.\*, I. **Imig, J.\***



**Summary impact factor all publications:**

a. cumulative impact factor: **179.6**

b. composed as followed:

Journal	number papers	impact factor	<b>cumulative impact factor</b>
Genes Development	1	12.64	<b>12.64</b>
Cancer Cell	2	22.84	<b>45.68</b>
Cell Death Diff	1	8.18	<b>8.18</b>
Genome Research	1	14.63	<b>14.63</b>
Nucleic Acid Research	2	9.13	<b>18.26</b>
Plos One	3	3.2	<b>9.6</b>
Int. J. Cancer	3	5.08	<b>15.24</b>
Nature Chemical Biology	1	12.99	<b>12.99</b>
Nature Communications	1	11.47	<b>11.47</b>
Virchow Archives	1	2.65	<b>2.65</b>
Cancer Medicine	1	2.5	<b>2.5</b>
BioMol Concepts	1	0	<b>0</b>
EMBO J	1	10.43	<b>10.43</b>
Mol Biol Cell	1	4.08	<b>4.08</b>
Blood	1	10.45	<b>10.45</b>
Anticancer Research	1	1.82	<b>1.82</b>
<b>sum</b>	<b>22</b>	<b>132.06</b>	<b>179.6</b>

h-Index:

c. **17**(source: Google Scholar) or **15** (source: Scopus)